^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma
Excerpt:
The clinical data of 36 NSCLC patients with EGFR mutation who received TKI treatment were retrospectively analyzed....Of the 32 patients who continued to receive EGFR-TKI treatment, 15 received third-generation TKI, including 13 patients with positive EGFR T790M mutations...Patients with T790M mutations achieved longer PFS than EGFR T790M mutation-negative patients…
DOI:
10.21037/tlcr-20-679
